Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks ...

China, one of the countries affected by the new tariffs, is the world’s largest producer of active pharmaceutical ingredients ...

AI’s role in healthcare evolved significantly in 2024. Rather than generic AI solutions, startups focused on specialized, ...

The FDA has approved Avtozma® (tocilizumab-anoh), a biosimilar to Actemra®, in both intravenous and subcutaneous formulations.

A recombinant anti-CD38 fully human monoclonal antibody injection, HLX15 comes in both intravenous and subcutaneous formulations. Henlius will oversee development, manufacturing a ...

The FDA's approval is grounded in an evidence totality and comprehensive data package, which includes outcomes from a study.

The US Food and Drug Administration (FDA) has approved Avtozma (tocilizumab-anoh) as a biosimilar of the original reference biologic tocilizumab (Actemra), according to a January 30 announcement ...

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules President Region International, Francisco Ballester, to retire as of March 1, 2025, after 34 years of servicePeter Stenico, ...

HYDERABAD -Indian biopharmaceutical firm Biocon is likely to list its key biosimilars business by March 2026 and aims for a double-digit share in its core U.S. market for its new launches ...

With patents on originator biologic medicines beginning to expire in the United States, there’s a growing opportunity for biosimilars to enter the market as alternative therapeutic options at ...

Presentation Unidentified Speaker Thank you. Thank you, Julianne. Good afternoon, everyone, and welcome to our 4th-quarter ...

The new biosimilar, Celltrion’s Avtozma, was approved in both IV and subcutaneous forms to treat inflammatory conditions such as arthritis. The FDA has approved Celltrion’s similar of Genentech’s ...